Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05200481
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-07
First Post:
2022-01-07
Brief Title:
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer MASTERPROTOCOL ALK
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Intergroupe Francophone de Cancerologie Thoracique
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-18
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-10
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-07
First Submit QC Date:
January 7 2022
Study First Post Date:
2022-01-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-09
Last Update Post Date:
2024-03-07
Last Update Post Date Type:
ACTUAL